Key Efficacy and Safety Considerations for Payers in ATTR-CM

This episode, titled ‘Key Efficacy and Safety Considerations for Payers in ATTR-CM,’ features the experts examining the long-term extension data for tafamidis and acoramidis and what it reveals about durability of benefit, and how payers should weigh this evidence. Dr. Alexander highlights two key findings from the tafamidis open-label extension: patients who crossed over from placebo never fully caught up to those on continuous treatment, reinforcing the importance of early intervention, and the 80 mg dose demonstrated a clearer benefit over the 20 mg dose in the longer-term data, informing the current preferred dosing standard. Similarly, the acoramidis extension data showed continuous treatment outperformed delayed treatment, and tafamidis add-on therapy did not appear to provide additional benefit on top of acoramidis.

When summarizing the most clinically meaningful efficacy findings across the three trials, Dr. Alexander highlights distinct takeaways from each. ATTR-ACT demonstrated a significant mortality reduction even in a sicker patient population. ATTRibute-CM showed early cardiovascular hospitalization curve separation at just three months, suggesting rapid clinical impact, along with biomarker data linking serum TTR levels to hospitalization outcomes. Helios-B demonstrated meaningful benefit even in patients already on background tafamidis, raising the possibility that combination therapy may offer additional advantages in select patients, a question that upcoming trials such as Cardiotransform may help answer.

On safety, Dr. Alexander notes that all three agents carry favorable profiles. Tafamidis has reported drug interactions with statins that are manageable through dose reduction and monitoring. Acoramidis has rare reports of gastrointestinal side effects. Vutrisiran requires daily vitamin A supplementation due to its mechanism lowering transthyretin levels, with potential risks of deficiency including night blindness and dermatologic conditions, though these are uncommon in clinical practice. Dr. Haumschild concludes that the manageable safety profiles across all three agents limit their broader economic impact for payers.

In the next episode, 'Assessing Clinical and Economic Factors in Treatment Selection and Payer Decision-Making,' panelists will continue their discussion on ATTR-CM and highlight the clinical and economic factors that guide therapy selection between TTR stabilizers, silencers, and combination approaches, while examining how shared decision-making, patient-specific factors, and real-world evidence generation inform both provider and payer decisions.